Donald Metcalf, M.D., the physiologist renowned as “the father of hematopoietic cytokines” for his pioneering work on the control of blood cell formation, will receive the American Association for Cancer Research Award for Lifetime Achievement in Cancer Research.
A method of screening women in Ghana for early signs of cervical cancer and providing preventive treatment at the same visit appears to be safe, acceptable to women and feasible, according to a study by a researcher at the Stanford University School of Medicine.
Actigraphy, the use of a portable device that records movement over extended periods of time, and has been used extensively in the study of sleep and circadian rhythms, provides an acceptably accurate estimate of sleep patterns in normal, healthy adult populations and in-patients suspected of certain sleep disorders, according to practice parameters published in the April 1st issue of the journal SLEEP.
Roche announced that their innovative cancer drug Avastin (bevacizumab) has been approved in Europe for the treatment of women with metastatic breast cancer.
French CNRS scientists in collaboration have shown that a memory of a traumatic event can be wiped out, although other, associated recollections remain intact.
The U.S. Food and Drug Administration (FDA) licensed Ceprotin, the first biologic treatment for patients with a rare genetic defect that can cause a potentially life-threatening clotting disorder.
The Center for Applied Medical Research (CIMA) from the University of Navarra and the Amsterdam Molecular Therapeutics BV (AMT) have demonstrated the pre-clinical effectiveness of a treatment against acute intermittent porphyria.
Solvay Pharmaceuticals, Inc., Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), and Lundbeck A/S presented clinical study results on bifeprunox at an international medical congress this week.
The European Commission approved Xeloda in combination with platinum-based chemotherapy, for first-line use in patients with advanced stomach cancer.
In studies in mouse models, researchers at the University of California, San Diego (UCSD) School of Medicine have found that a cellular receptor involved in triggering cell death is also a necessary component of tissue repair and regeneration immediately following liver injury. This discovery could have implications for early intervention or therapy in liver disease such as cirrhosis or hepatitis.